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ABSTRACT
Methylphenidate, which blocks the presynaptic norepinephrine and 
dopamine transporters, is the most common used medication and 
offered as first choice in the treatment guidelines of attention deficit 
hyperactivity disorder (ADHD). One of its rarely seen adverse 
effects is, hallucinations that can be formed idiosyncratically, 
which can be correlated with increased dopaminergic functioning 
in synaptic cleft. We will present an eight year old boy diagnosed 
with ADHD-combined type, and oppositional defiant disorder 
(ODD) with no previous medical and family history who has 
impulsively taken extra dose of methylphenidate in the course of 
usual drug treatment. The acute hallucinosis presentation which 
has subsided the next day completely with the cessation of drug 
treatment will be discussed.
Keywords: Methylphenidate, Hallucinosis, Attention deficit 
hyperactive disorder
ÖZ
Presinaptik norepinefrin ve dopamin taşıyıcılarını bloke eden 
metilfenidat, dikkat eksikliği  hiperaktivite bozukluğu (DEHB) 
tedavisinde en sık kullanılan ve tedavi rehberlerinde birinci  tercih 
olarak sunulan ilaçtır. Nadir karşılaşılan yan etkilerinden biri de, 
sinaptik aralıktaki artmış dopaminerjik işleyiş ile ilişkilendirilen, 
idiosenkratik oluşabilen varsanılardır. Polikliniğimizde DEHB-
bileşik tip ve karşıt olma karşı gelme bozukluğu (KOKGB) teşhisi 
konularak metilfenidat tedavisine başladığımız, özgeçmiş ve 
soygeçmişinde herhangi bir hastalık öyküsü bulunmayan sekiz 
yaşındaki erkek bir çocukta, olağan ilaç tedavisi sırasında impulsif 
bir şekilde aldığı fazladan bir doz kısa etkili metilfenidat ile 
gelişen ve ilacın kesilmesiyle birlikte ertesi gün tümüyle gerileyen 
halüsinoz tablosunu tartışacağız.
Anahtar kelimeler: Metilfenidat, Halüsinoz, Dikkat eksikliği 
hiperaktivite bozukluğu
Introduction
Attention deficit hyperactivity disorder (ADHD) is one 
of the most common neurodevelopmental disorder in 
school age children. It is  a heterogeneous disorder which 
is composed of core symptoms including hyperactivity, 
attention deficit and impulsivity. Short and long 
acting methylphenidate (MPH), amphetamine, mixed 
amphetamine salts, and atomoxetine are utilized for the 
pharmacologic treatment [1]. Methylphenidate is the 
most commonly used agent and it is the first option in 
treatment.  MPH acts via specifically blocking presynaptic 
norepinephrine and dopamine transporters, impedes their re-
uptake thereby increases their levels in synaptic cleft [2,3]. 
MPH is safely used in children, adolescents and adults due 
to its low adverse effect profile. Among the most common 
adverse effects; sleeplessness, stomachache, headache, 
loss of appetite, irritability and anxiety can be considered. 
Relatively less commonly, tics and emotional fluctuations 
also can be seen [4]. In addition, in 1971 Lucas and Weiss, 
mentioned short lasting psychotic symptoms in patients 
who utilize methylphenidate  [5]. In the current literature, 
“hallucinosis” and “toxicosis” terms are particularly used 
in order to differentiate temporary symptoms related to 
stimulants in contrast to permanent psychotic symptoms 
that are  seen in schizophrenia and bipolar disorder [6]. 
Hallucinosis is described as the presence of complex 
auditory or visionary halucinations with preserved insight. 
There are no delusions or altered consciousness and 
temporarily it is defined as “pseudohallucinations” [7]. In 
literature, occurrence of hallucinations are considered as 
the end result of commonly high dose oral methylphenidate 
usage besides parenterally usage [8]. It is designated that 
this explicit mental state is short lasting, generally limits 
itself within a few hours and its possible ethiopathogenesis 
is chiefly related with increase in concentration of synaptic 
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dopamine [4]. This presentation could be observed even 
after the first or low dose methylphenidate ingestion and 
idiosyncratic mechanisms have been speculated [3]. If 
abrupt pyschosis symptoms are observed as adverse effects 
of stimulants used for ADHD treatment, then the cessation of 
stimulant treatment and switching to atomoxetine treatment 
is recommended [9]. In this article, an eight year old male 
child patient who had hallucinosis after an overdose during 
regular MPH usage with therapeutic dosages is presented. 
Case Report
An eight year old male patient, referred to Marmara 
University Faculty of Medicine, Child and Adolescent 
Psychiatry Outpatient Clinic  by his teacher because of his 
“disobedience to rules, overactivity, irritability, attention 
deficit and academic underachievement” symptoms. 
According to clinical history obtained from his mother and 
father, he is always  overactive, inpatient and generally he 
does not have anger management problems and he never 
gets to a point of harming another person. He was born with 
normal delivery from a first degree inter marriage (with 
cousin), in a hospital without any complications. There are no 
significant characteristics in his developmental background. 
His speech development and walking are within expected 
age range. There is no psychiatric disorder mentioned in his 
family and close relatives.
During detailed psychiatric examination, he made eye 
contact but looked out of the window frequently and he was 
constantly moving. In mental status examination, his place, 
time and person orientation was normal. He was easily 
distractible and it is hard for him to concentrate on interview. 
His mood was euthymic and affect was appropriate with 
his mood. His thought content was congruent with his age 
and affect. Any perception defect has not been defined. 
There was not  any anxious and behavioral symptoms. He 
did not describe any problems with falling asleep or sleep 
maintenance. His appetite was normal. His speech was 
fast but comprehensible and logical. Generally he was 
responding without waiting for the end of the question. 
He was reading the material syllable by syllable by 
following with his finger. He often omitted and added letters 
and confused letters by mistake. Also while he was writing 
although he was very slow and cautious, still he did more 
misspelling than expected according to his age. His right and 
left discrimination was developed. 
As a result of the interview which is examined according 
to The Diagnostic and Statistical Manual of Mental Disorders 
(DSM-4-TR) criteria, the patient was diagnosed with 
ADHD-combined type oppositional defiant disorder (ODD). 
Hemogram, biochemical tests and electrocardiography 
were planned as pretreatment evaluation. Due to the lack 
of episodic symptoms, pediatric neurology consultation 
and electroencephalography were not ordered. For possible 
learning disability co-occurrence, Weschsler Intelligence 
Scale for Children-revised (WISC-R) was planned. 
After his examinations short acting methylphenidate 
medication was given first as 5 mg in the morning and 
5mg  at noon. The dosage was gradually increased with 
the absence of any adverse effect, as 10 mg in the morning 
and 10mg  at noon, total 20 mg/day was reached. For 
oppositional defiant behaviors, behavioral advices were 
given to the parents. When the patient admitted for next 
appointment his parents stated that their son’s symptoms 
were decreased after the medication and his teacher was also 
glad. Soon after the dosage increase, they mentioned that 
they had an unusual situation in a night. The patient told his 
doctor that the medicine worked well and he  wanted more. 
This acute state occurred after the patient ingested extra 
dose of two 10 mg short acting MPH without his parents’ 
knowledge at nighttime. As the parents estimated, 2 hours 
after the ingestion of medicine, he described the sounds 
of meowing and screaming cats in the kitchen; auditory 
and visual hallucinations like footsteps from outside. He 
mentioned that everything was moving and when his father 
came the cats suddenly escaped. In that particular time, he 
did not show any fear or anxiety symptoms. That night he 
could not  fall asleep till morning and had a short restless 
sleep. When he woke up in the morning, there were no 
symptoms. After this event, his parents ceased the drug. 
When the patient came to his follow-up appointment, there 
was not  any psychotic symptoms.  The parents were highly 
worried and did not want to continue to use the medication. 
WISC-R examination revealed as subscores of verbal 
intelligence: 96, performance intelligence: 99 and total 
intelligence: 97. Those scores were interpreted as within the 
normal intellectual range. The subscores of WISC-R did not 
support learning disability (LD).
Discussion
In our case report, we present an eight year old boy patient 
who experienced hallucinosis after impulsively taking an 
extra dose of short acting MPH. Although it is  considered 
that the presence of hallucinations and psychosis are used 
as alternative explanations, in children this relation is 
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rarely observed together. For the differential diagnosis, 
developmental stage of the child, the presence of any 
neurological disorder, stressful life events, cultural belief 
factors such as the effect of witches, ghosts and other 
spiritual beliefs, any other pscyhiatric disorder, medical 
conditions and overdose drug ingestion as our patient 
committed should be considered [10]. 
There are many cases who experienced abrupt psychotic 
features which is related to MPH usage in literature 
[11]. At therapeutic dosages of stimulants, frequency of 
psychotic symptoms is around  0.25% [9]. Seeing snakes, 
flies, cockroaches, mice, and meowing cats as our case 
presented and vivid hallucination themes are commonly 
encountered [11]. The time period of the appearance of 
hallucinations which defined as commonly sensorial and 
the ingestion of MPH may differ person to person [7,11]. 
Short lasting and self- limited psychotic features after 
ingesting extra doses of stimulants can be experienced 
independently from current psychological state of people 
[8]. It is claimed that stimulants that are taken above the 
therapeutic doses cause visual stimulation that can be 
perceived diversely due to the mechanism of the increased 
norepinephrine in lateral geniculate nucleus resulting an 
accelerated visual information flow [3]. These experiences 
mostly subside following the cessation of the medication 
like in our patient [10]. Carkaxhıu and colleagues, reported 
a retrospective review study of 60 stimulant-induced 
psychosis cases and in only 5% of them the symptoms 
were continuing despite the cessation of medication [4]. 
During the follow-up of our patient, there were not  any 
psychotic signs and symptoms observed. 
Dose-response relationship is well-defined in MPH 
treatment and with relatively higher doses. Better 
clinical responses in the presence of higher adverse 
effects are observed during the treatment. It is  observed 
that  therapeutic effects and serum concentrations of fast 
releasing MPH run parallel to each other and most of the 
symptomatic remission occurs within 1,5-2 hours after 
taking the medication [4,12,13]. And that time period 
was concordant with the beginning of the hallucinosis 
in our patient. Personal response differences for MPH is 
considered as a result of individualized dopamine and/or 
norepinephrine system responses [11]. Dopamine system 
consists of two main ascending systems. The first one starts 
from the substantia nigra and ends at striatum and includes 
nigrostriatal system that is composed of caudate nucleus and 
putamen. The other one is the mesocorticolimbic pathway 
which receives dopaminergic inputs from mesencephalon 
[14]. The most specific regions that MPH binds are the 
terminal regions of nigrostriatal and mesolimbic pathways. 
These dopaminergic structures are also responsible for the 
effect of medications [15].  The relation between dopamine 
and psychotic presentation is also well-defined. Dopamine 
which is found in high levels in limbic system is accepted 
as having a key role in hallucination formation [10]. 
In an investigation study of amphetamine triggered 
psychosis cases, the importance of dopaminergic effect in 
central nervous system is emphasized. It is stated that there 
might be a personal predisposition for over production of 
dopamine receptor subtype 2 (DRD2) which may lead to 
over-production of DRD2 [16].
Clinical studies offer a personal difference in response 
to stimulant treatment independent from the factors 
like age, weight and drug metabolism. Some of these 
differences are explained with phenotypic differences 
like  healthy volunteers, the ones who abuse drugs and the 
patients diagnosed as ADHD [12,17]. The monitorization 
study which is conducted by positron emission tomography 
(PET) revealed that dopaminergic changes in brain may 
have huge personal variety [18]. Because of polymorphism 
of carboxylesterase 1 enzyme which metabolize MPH 
primarily, MPH rises to unexpected high doses [17,19]. 
Although it is not clearly denoted as psychosis, another 
group which is prone to stimulants’ adverse effects is the 
group  who has neurodevelopmental disorders like mental 
retardation and autism [13]. In our patient, there was not 
any developmental disorder explained that might cause 
hypersensitivity to adverse effects of stimulants. Despite 
the absence of a particular etiologic factor that could 
explain the hallucinosis in our case, it is considered to be 
caused by individualized over reaction of dopaminergic 
pathways to acute MPH stimulation 
Psychotic perception experiences with MPH can be 
very worrying for both child and the family although it is 
seen rarely. At the same time, it is clear that this situation 
will be a milestone for treatment continuity in family, 
children and doctor. Being cautious is highly important for 
the clinicians for this rarely seen adverse effect of MPH. 
With our patient’s own explanation for ingesting over dose 
of MPH  for the sake of “a better treatment”, it should bring 
to our mind that a patient  can easily ingest  the medication 
with an impulsive behavior thinking that taking higher 
doses of  MPH will lead to a better therapeutic response. 
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